The Valley Hospital’s visitation guidelines are at risk Level Yellow. Learn more.Read More
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery (REFRESH II Trial)
To study the incidence or severity of acute kidney injury (AKI) in the first 48 hours after cardiopulmonary bypass.
- Experimental: CytoSorb® Device
- Placebo Comparator: Control
- Scheduled for non-emergent cardiac surgery requiring CPB for i) heart valve replacement with any other procedure, without hypothermic circulatory arrest (HCA), or ii) aortic reconstruction with or without another procedure, with HCA